550 related articles for article (PubMed ID: 11351299)
1. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
2. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
3. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
4. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
7. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.
Farid P; Gomb SZ; Péter I; Szende B
Neoplasma; 2001; 48(4):299-301. PubMed ID: 11712682
[TBL] [Abstract][Full Text] [Related]
8. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene.
Sturm I; Papadopoulos S; Hillebrand T; Benter T; Lück HJ; Wolff G; Dörken B; Daniel PT
Int J Cancer; 2000 Aug; 87(4):517-21. PubMed ID: 10918191
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
12. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland.
Branet F; Brousset P; Krajewski S; Schlaifer D; Selves J; Reed JC; Caron P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2726-30. PubMed ID: 8675602
[TBL] [Abstract][Full Text] [Related]
13. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
14. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
[TBL] [Abstract][Full Text] [Related]
15. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
Rau B; Sturm I; Lage H; Berger S; Schneider U; Hauptmann S; Wust P; Riess H; Schlag PM; Dörken B; Daniel PT
J Clin Oncol; 2003 Sep; 21(18):3391-401. PubMed ID: 12885834
[TBL] [Abstract][Full Text] [Related]
16. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Shi Y; Zou M; Farid NR; al-Sedairy ST
Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
18. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
[TBL] [Abstract][Full Text] [Related]
20. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
